In another Actos case, a Philadelphia state court jury, ordered Takeda Pharmaceuticals to pay more than $2 million for failing to warn doctors that its diabetes drug Actos could cause bladder cancer. The case is the seventh Actos case to go to trial nationwide and it comes on the heels of the $9 billion verdict referred to above. In 2013, juries in California and Maryland ordered Takeda to pay more than $8 million in damages, but those verdicts were overturned by the judges for technical reasons. Juries in three trials, two in Las Vegas and one in Chicago, have returned verdicts in favor of Takeda. There are still more than 8,000 cases pending against Takeda Pharmaceuticals and its co-marketer of Actos, Eli Lily, in both federal and state courts. These cases allege that Actos causes bladder cancer. More trials are scheduled for late 2014 and continue throughout 2015.
The Philadelphia jury found that Takeda failed to warn the doctors of 79-year-old Plaintiff Frances Wisniewski that Actos increases the risk of developing bladder cancer. The jury heard testimony – which was presented during the federal trial in Louisiana – about Takeda’s destruction of key employees’ documents. Even though it heard that testimony, the jury failed to order Takeda Pharmaceuticals to pay punitive damages.
Andy Birchfield and Roger Smith, lawyers in our firm’s Mass Torts Section, continue to investigate claims on behalf of individuals and families injured by Actos. Thus far the lawyers and support staff have investigated 2,100 separate Actos claims. If you need more information on the Actos litigation, contact Andy Birchfield or Roger Smith at 800-898-2034 or by email at Andy.Birchfield@beasleyallen.com or Roger.Smith@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.